LEXEO THERAPEUTICS INC (LXEO) Fundamental Analysis & Valuation

NASDAQ:LXEO • US52886X1072

Current stock price

5.85 USD
-0.16 (-2.66%)
At close:
5.85 USD
0 (0%)
After Hours:

This LXEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. LXEO Profitability Analysis

1.1 Basic Checks

  • In the past year LXEO has reported negative net income.
  • In the past year LXEO has reported a negative cash flow from operations.
  • In the past 5 years LXEO always reported negative net income.
  • In the past 5 years LXEO always reported negative operating cash flow.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • With a Return On Assets value of -37.20%, LXEO perfoms like the industry average, outperforming 57.48% of the companies in the same industry.
  • LXEO's Return On Equity of -40.52% is fine compared to the rest of the industry. LXEO outperforms 67.38% of its industry peers.
Industry RankSector Rank
ROA -37.2%
ROE -40.52%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LXEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LXEO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, LXEO has more shares outstanding
  • Compared to 5 years ago, LXEO has more shares outstanding
  • Compared to 1 year ago, LXEO has an improved debt to assets ratio.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 9.26 indicates that LXEO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 9.26, LXEO belongs to the top of the industry, outperforming 80.78% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that LXEO is not too dependend on debt financing.
  • LXEO has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.26
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

  • LXEO has a Current Ratio of 11.21. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
  • LXEO has a Current ratio of 11.21. This is amongst the best in the industry. LXEO outperforms 82.52% of its industry peers.
  • LXEO has a Quick Ratio of 11.21. This indicates that LXEO is financially healthy and has no problem in meeting its short term obligations.
  • LXEO's Quick ratio of 11.21 is amongst the best of the industry. LXEO outperforms 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 11.21
Quick Ratio 11.21
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. LXEO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 28.90% over the past year.
EPS 1Y (TTM)28.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, LXEO will show a very strong growth in Earnings Per Share. The EPS will grow by 23.83% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.4%
EPS Next 2Y16.9%
EPS Next 3Y16.95%
EPS Next 5Y23.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. LXEO Valuation Analysis

4.1 Price/Earnings Ratio

  • LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LXEO's earnings are expected to grow with 16.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.9%
EPS Next 3Y16.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LXEO Dividend Analysis

5.1 Amount

  • No dividends for LXEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LXEO Fundamentals: All Metrics, Ratios and Statistics

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (4/24/2026, 8:00:01 PM)

After market: 5.85 0 (0%)

5.85

-0.16 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-07
Inst Owners104.14%
Inst Owner Change-0.01%
Ins Owners0.84%
Ins Owner Change5.28%
Market Cap433.43M
Revenue(TTM)N/A
Net Income(TTM)-99.96M
Analysts88.24
Price Target19.99 (241.71%)
Short Float %18.73%
Short Ratio13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.81%
Min EPS beat(2)15.85%
Max EPS beat(2)37.78%
EPS beat(4)3
Avg EPS beat(4)10.8%
Min EPS beat(4)-23.91%
Max EPS beat(4)37.78%
EPS beat(8)6
Avg EPS beat(8)3.85%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)-1.55%
EPS NQ rev (1m)9.37%
EPS NQ rev (3m)9.37%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.76
P/tB 1.76
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS3.33
TBVpS3.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -37.2%
ROE -40.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.21
Quick Ratio 11.21
Altman-Z 9.26
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.38%
EPS Next Y37.4%
EPS Next 2Y16.9%
EPS Next 3Y16.95%
EPS Next 5Y23.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.66%
EBIT Next 3Y-8.54%
EBIT Next 5Y-9.49%
FCF growth 1Y-36.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.4%
OCF growth 3YN/A
OCF growth 5YN/A

LEXEO THERAPEUTICS INC / LXEO Fundamental Analysis FAQ

What is the fundamental rating for LXEO stock?

ChartMill assigns a fundamental rating of 2 / 10 to LXEO.


Can you provide the valuation status for LEXEO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to LEXEO THERAPEUTICS INC (LXEO). This can be considered as Overvalued.


How profitable is LEXEO THERAPEUTICS INC (LXEO) stock?

LEXEO THERAPEUTICS INC (LXEO) has a profitability rating of 1 / 10.